Ansari M T, Loothar B A, Khan Q J
Department of Pharmacy, Bahaudin Zakaria University, Multan.
Pak J Pharm Sci. 2001 Jan;14(1):13-7.
The effect of naproxen (500 mg) on the pharmacokinetics of rifampicin (450 mg) was evaluated in healthy human subjects (n = 10). Subjects participated in a two way crossover trial, the first dosing condition was rifampicin alone (control), and the second dosing condition was naproxen with rifampicin. The concentrations of rifampicin from the serum samples were determined by HPLC. The pharmacokinetic parameters indicated a significant (P < 0.05) increase in elimination rate constant (Ke), clearance (Cl), volume of distribution (Vd), while significant decrease in the mean residence time (MRT), and area under the concentration-time curve (AUC). Insignificant increase and decrease in absorption rate constant (Ka), and elimination half-life (t1/2), time for maximum concentration (Tmax), maximum drug concentration (Cmax) respectively was observed.
在健康人类受试者（n = 10）中评估了萘普生（500毫克）对利福平（450毫克）药代动力学的影响。受试者参与了一项两交叉试验，第一个给药条件是单独使用利福平（对照），第二个给药条件是萘普生与利福平联用。通过高效液相色谱法测定血清样本中利福平的浓度。药代动力学参数表明消除速率常数（Ke）、清除率（Cl）、分布容积（Vd）显著（P < 0.05）增加，而平均驻留时间（MRT）和浓度-时间曲线下面积（AUC）显著降低。分别观察到吸收速率常数（Ka）、消除半衰期（t1/2）、达峰时间（Tmax）、最大药物浓度（Cmax）无显著增加和降低。
